$ATEX

Anterix Inc.

0
2
0

No SEC Form 4 filings for $ATEX in the last 30 days.

Low

Anterix Shareholders Approve Board, Pay and Expanded 2023 Stock Plan

Anterix Inc. (NASDAQ:ATEX) shareholders approved the board and pay proposals and Amendment No. 2 to the company’s 2023 Stock Plan, which increases shares available for employee and non-employee director issuance. Stockholders also set an annual frequency for non-binding say-on-pay votes, and ratified Deloitte & Touche as independent auditor for FY ending March 31, 2027. Final results will be filed on Form 8-K.

Anterix Inc. (ATEX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Anterix Inc. (ATEX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. atex-20260804 FALSE 0001304492 3 Garret Mountain Plaza Suite 401 Woodland Park NJ 0001304492 2026-08-04 2026-08-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 193

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More

24/7 Wall St. lists Tuesday analyst calls. Bank of America upgraded Honeywell (HON) to Neutral and set $265, while UBS upgraded Intuitive Surgical (ISRG) to Buy with $550. Downgrades include Clorox (CLX) to Hold with $98, Intuit (INTU) to Hold with $304, and Exxon (XOM) to Neutral with $158. Initiations: CrowdStrike (CRWD) Buy $230, Boston Scientific (BSX) Buy $74.

ATEX sentiment & insider activity

Over the past 7 days, alphai's AI scored 2 news stories mentioning ATEX (Anterix Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.

Recent ATEX coverage spans insider activity, corporate actions and earnings.

What's driving ATEX

  • The vote is a corporate governance and equity-plan update that can affect dilution expectations and employee retention incentives, but it is not a fundamental earnings catalyst.

    yahoo.com · Aug 7, 2026

  • Share-plan expansion can modestly increase future dilution expectations, but the filing is primarily governance and does not change near-term fundamentals by itself.

    SEC EDGAR 8-K · Aug 6, 2026

  • New coverage with a high target can attract fresh speculative and fundamental buyers.

    247wallst.com · Jul 28, 2026

  • Routine insider sale disclosed via SEC Form 4; it signals liquidity/portfolio activity more than a fundamental change.

    SEC EDGAR · Jun 18, 2026

  • Insider selling is a modest negative signal, but it is not a fundamental catalyst by itself.

    SEC EDGAR · Jun 17, 2026

alphai scores every news story that mentions ATEX with an AI model for sentiment and relevance, and aggregates insider trades from Anterix Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ATEX

Score
$ATEXLow

Anterix Shareholders Approve Board, Pay and Expanded 2023 Stock Plan

Anterix Inc. (NASDAQ:ATEX) shareholders approved the board and pay proposals and Amendment No. 2 to the company’s 2023 Stock Plan, which increases shares available for employee and non-employee director issuance. Stockholders also set an annual frequency for non-binding say-on-pay votes, and ratified Deloitte & Touche as independent auditor for FY ending March 31, 2027. Final results will be filed on Form 8-K.

Anterix Inc. (ATEX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Anterix Inc. (ATEX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. atex-20260804 FALSE 0001304492 3 Garret Mountain Plaza Suite 401 Woodland Park NJ 0001304492 2026-08-04 2026-08-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 193

$HONMed

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Boston Scientific, Clorox, CrowdStrike, Exxon Mobil, Honeywell International, Intuit, Intuitive Surgical, Levi Strauss, and More

24/7 Wall St. lists Tuesday analyst calls. Bank of America upgraded Honeywell (HON) to Neutral and set $265, while UBS upgraded Intuitive Surgical (ISRG) to Buy with $550. Downgrades include Clorox (CLX) to Hold with $98, Intuit (INTU) to Hold with $304, and Exxon (XOM) to Neutral with $158. Initiations: CrowdStrike (CRWD) Buy $230, Boston Scientific (BSX) Buy $74.

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2

Related tickers